Strongbridge is an agile organization that focuses on developing and commercializing treatments for patients with rare diseases. Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options.Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products. The Company's franchise-based model allows leveraging company expertise—in both the clinical and commercial development realms—to provide a range of therapeutically-aligned products.